---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-26-000097"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2026-07-23T11:14:59+00:00"
generated_at: "2026-07-23T11:20:10.069144+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q2 net sales up 13.8%, adjusted EPS $2.37 (+28.8%); raises full-year guidance

## Summary
- Q2 net sales $872.3M (+13.8% reported, +12.7% organic); adjusted-diluted EPS $2.37 (+28.8%).
- Full-year 2026 net sales guidance raised to $3.345B-$3.380B; adjusted EPS guidance raised to $8.85-$9.05.
- HVP Components net sales $424.1M (+19.4%); HVP Delivery Devices $131.2M (+29.6%) driven by Biologics and GLP-1 elastomers.
- Q3 2026 guidance: net sales $820M-$835M, adjusted EPS $2.14-$2.24.
- Repurchased 1.8M shares for $454.3M in H1 2026; declared Q3 dividend $0.22/share.

## SEC filing metadata
- accession: 0000105770-26-000097
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2026-07-23T11:14:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/0000105770-26-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/wst-20260723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-26-000097
- JSON: https://secwatch.observer/filing/0000105770-26-000097.json
- Plain text: https://secwatch.observer/filing/0000105770-26-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.